Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Alliances are going to help community oncology participate in things that, as individual practices, they don‘t have the opportunity to do, said Barry Russo, chief executive officer of The Center for Cancer and Blood Disorders.
Transcript
How will alliances among practices affect the future of cancer care?
I think they’re essential for the future of cancer care because without alliances, you don’t have the scale and scope to really participate in all the things that are coming down the pike. Artificial intelligence is not cheap, it’s expensive. New technology is not cheap, it’s expensive. Payer contracting and employer contracting and that’s what a lot of us are really hoping in the future happens, that the employers who are the real payers, that we can have direct relationships with them. All of that requires size and scale and I think those alliances are going to help community oncology participate in things that, as individual practices, we just don‘t have the opportunity to do so.
It was really the theory behind the whole start of US Oncology, and the theory behind Florida Cancer [Specialists] in American Oncology and the theory behind the sort of blossoming OneOncology alliance that’s developing a little more formal, a little more structured, but is that size and scale can really help you in the technology world and in the payer world and in the developing [accountable care organization] and employer market world.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More